Discontinued — last reported Q1 '26
Business Segments · R&D
Pharmaceutical — R&D
This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ1 2022
Last reportedQ1 2026
Rolls up toR&D
How to read this metric
Higher investment is generally positive for long-term growth, provided it leads to a robust pipeline of successful drug candidates.
Detailed definition
Expenditures dedicated to the discovery, clinical testing, and regulatory approval of new pharmaceutical products. This...
Peer comparison
Major pharma companies typically invest 15-25% of revenue back into R&D to sustain long-term competitiveness.
Metric ID:
mrk_segment_pharmaceutical_segment_research_and_developmentHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Range$0.00 – $0.00
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s pharmaceutical — r&d?
- Merck & Co. (MRK) reported pharmaceutical — r&d of $0.00 in Q1 2026.
- What does pharmaceutical — r&d mean?
- Investment in the discovery and development of new pharmaceutical products.